(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(0.26%) $78.31
(0.33%) $2.15
(0.50%) $2 320.10
(1.73%) $27.15
(-0.41%) $961.35
(0.00%) $0.929
(-0.07%) $10.87
(-0.02%) $0.797
(0.00%) $91.45
@ $25.17
发出时间: 14 Feb 2024 @ 22:30
回报率: -14.58%
上一信号: Feb 13 - 22:31
上一信号:
回报率: -0.59 %
Live Chart Being Loaded With Signals
Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally...
Stats | |
---|---|
今日成交量 | 355 667 |
平均成交量 | 216 209 |
市值 | 640.37M |
EPS | $0 ( 2024-05-03 ) |
下一个收益日期 | ( $-0.320 ) 2024-05-16 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -3.87 |
ATR14 | $0.0290 (0.13%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-05-01 | Hsieh Ming | Sell | 1 337 | Common Stock |
2024-04-30 | Gao Hanlin | Sell | 79 | Common Stock |
2024-04-26 | Xie Jian | Sell | 4 344 | Common Stock |
2024-04-26 | Kim Paul | Sell | 2 738 | Common Stock |
2024-04-26 | Gao Hanlin | Sell | 1 154 | Common Stock |
INSIDER POWER |
---|
1.33 |
Last 99 transactions |
Buy: 2 001 398 | Sell: 1 963 075 |
音量 相关性
Fulgent Genetics Inc 相关性 - 货币/商品
Fulgent Genetics Inc 财务报表
Annual | 2023 |
营收: | $289.21M |
毛利润: | $96.61M (33.40 %) |
EPS: | $-5.63 |
FY | 2023 |
营收: | $289.21M |
毛利润: | $96.61M (33.40 %) |
EPS: | $-5.63 |
FY | 2022 |
营收: | $618.97M |
毛利润: | $366.90M (59.28 %) |
EPS: | $4.76 |
FY | 2021 |
营收: | $992.58M |
毛利润: | $777.05M (78.29 %) |
EPS: | $17.25 |
Financial Reports:
No articles found.
Fulgent Genetics Inc
Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. The company offers genetic tests comprising Focus and Comprehensive oncology panels tests; Beacon carrier screening panels test for inherited conditions; solid tumor molecular profiling for somatic cancer testing; rapid whole genome testing for children in NICU and PICU; newborn genetic analysis panel; single front-line test to detect ataxia-related variants and repeat expansions through sequencing; picture genetics, a patient-initiated genetic testing; whole exome and clinical exome panel tests; whole genome, mutation, and repeat expansion testing services, as well as research service tests. It also provides next generation sequencing and reverse transcription polymerase chain reaction-based tests, as well as antigen-based diagnostic tests for the detection of SARS-CoV-2. In addition, the company offers flow cytometry, a cell analysis technique providing diagnosis, prognosis, and monitoring of malignancies; fluorescence in-situ hybridization for detecting and locating a specific DNA sequence on a chromosome; immunohistochemistry, an imaging technique used to visualize antigens in cells; cytogenetics, which analyzes the chromosome set for numerical and structural abnormalities; and molecular testing that includes hematopoietic and solid tumor molecular assays. The company serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. Fulgent Genetics has strategic partnership with Helio Health, Inc. to commercialize blood-based early cancer detection tests. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。